Literature DB >> 6537912

Sex hormone binding globulin (SHBG) in breast cancer: a correlation with obesity but not with estrogen receptor status.

A Sulkes, Z Fuks, A Gordon, J Gross.   

Abstract

Plasma sex hormone binding globulin (SHBG) levels were determined in a group of 82 patients suffering from breast carcinoma with a known estrogen receptor status (ER). Overweight (greater than 20% of ideal weight) premenopausal patients had a significantly lower SHBG plasma level than their non-obese counterparts (43 pmol/ml vs 72.7 pmol/ml, P less than 0.001). No difference in plasma levels of SHBG was found between obese and non-obese postmenopausal patients. No correlation was found between SHBG levels and ER status either in non-obese premenopausal patients or in postmenopausal patients in general. Breast carcinoma patients had significantly higher SHBG plasma levels than a group of normal controls (57.9 pmol/ml vs 40.6 pmol/ml, P less than 0.01), but the stage of the disease did not influence the SHBG level within the breast carcinoma patients. Results of this study do not support a correlation between SHBG levels and ER status. SHBG plasma levels are significantly influenced by a patient's weight, particularly in those who are premenopausal.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6537912     DOI: 10.1016/0277-5379(84)90029-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Genesis of breast cancer in Japanese: a possible relationship between sex hormone binding globulin (SHBG) and serum lipid components.

Authors:  O Takatani; T Okumoto; H Kosano
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

2.  Risk factors for adenocarcinoma of the cervix: a case-control study.

Authors:  F Parazzini; C La Vecchia; E Negri; M Fasoli; G Cecchetti
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

3.  Method for generating multiple risky barcodes of complex diseases using ant colony algorithm.

Authors:  Xiong Li; Wen Jiang
Journal:  Theor Biol Med Model       Date:  2017-02-01       Impact factor: 2.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.